Literature DB >> 25736215

Possible Impact of RET Polymorphism and Its Haplotypic Association Modulates the Susceptibility to Thyroid Cancer.

Mosin S Khan1, Arshad A Pandith2, Mohammad Iqbal1, Niyaz A Naykoo3, Shoukat H Khan4, Tanveer A Rather4, Syed Mudassar1.   

Abstract

Rearranged during Transfection (RET) gene polymorphisms act to influence thyroid cancer in a polygenic and low-penetrance manner and no study regarding RET alterations in thyroid cancer has undergone from this part of the world (North India). We evaluated RET G691S (rs1799939), L769L (rs1800861), and S904S (rs1800863) polymorphisms to elucidate their possible role as risk factors in papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). Polymorphic analysis of RET gene was performed by polymerase chain reaction (PCR), followed by restriction fragment length polymorphism (RFLP). In RET G691S polymorphism, the overall distribution of variant alleles (GA + AA) in cases was 62.9% as against 44.5% in controls (P < 0.05) whereas frequency of RET L769L variant alleles (TG + GG) in cases was 70% versus 88% in controls (P < 0.05). In RET S904S, frequency of variant alleles (CG + GG) in cases was 56% versus 44% in controls (P < 0.05). Interestingly, G691S/L769L variant showed increased risk for the non-smokers (P < 0.05). RET S904S variant showed association with benign thyroid disease as against those with no history. The over-representation of homozygotes in G691S and L769L polymorphic variants was not observed, which suggest a "Dominant mode of inheritance." The S904S polymorphism heterozygote lies almost in the middle of the two homozygotes confirming an "Additive mode of inheritance." In conclusion, RET gene G691S/S904S polymorphisms were over-represented and L769L polymorphism was under-represented in PTC and FTC patients. RET polymorphic variants could act synergistically in the development or progression of PTC and FTC.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  BENIGN THYROID DISEASE; REARRANGED DURING TRANSFECTION; THYROID CANCER; THYROID STIMULATING HORMONE

Mesh:

Substances:

Year:  2015        PMID: 25736215     DOI: 10.1002/jcb.25130

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  2 in total

1.  Associations between RET tagSNPs and their haplotypes and susceptibility, clinical severity, and thyroid function in patients with differentiated thyroid cancer.

Authors:  Caiyun He; Jiangjun Ma; Yongle Jiang; Xuan Su; Xiao Zhang; Weichao Chen; Zulu Ye; Tiancheng Deng; Wenze Deng; Ankui Yang
Journal:  PLoS One       Date:  2017-11-13       Impact factor: 3.240

Review 2.  Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates.

Authors:  Natalia Pstrąg; Katarzyna Ziemnicka; Hans Bluyssen; Joanna Wesoły
Journal:  Mol Cancer       Date:  2018-08-08       Impact factor: 27.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.